Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:35 PM
Ignite Modification Date:
2025-12-24 @ 1:35 PM
NCT ID:
NCT01210495
Eligibility Criteria:
Inclusion Criteria:
* Locally advanced or metastatic HCC
* Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.
* Child-Pugh Class A or B (score 7 only) disease.
Exclusion Criteria:
* Prior treatment of advanced HCC with more than one prior first-line systemic therapy.
* Any prior local therapy within 2 weeks of starting the study treatment.
* Presence of hepatic encephalopathy and/or clinically relevant ascites.
* Presence of main portal vein invasion by HCC.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01210495
Study Brief:
Protocol Section:
NCT01210495